174 related articles for article (PubMed ID: 21503586)
1. Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas.
Mupparaju S; Hou H; Lariviere JP; Swartz H; Jounaidi Y; Khan N
Oncol Rep; 2011 Jul; 26(1):281-6. PubMed ID: 21503586
[TBL] [Abstract][Full Text] [Related]
2. Tumor pO₂ as a surrogate marker to identify therapeutic window during metronomic chemotherapy of 9L gliomas.
Mupparaju S; Hou H; Lariviere JP; Swartz HM; Khan N
Adv Exp Med Biol; 2011; 701():107-13. PubMed ID: 21445776
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the changes in 9L and C6 glioma pO2 by EPR oximetry as a prognostic indicator of differential response to radiotherapy.
Hou H; Mupparaju SP; Lariviere JP; Hodge S; Gui J; Swartz HM; Khan N
Radiat Res; 2013 Mar; 179(3):343-51. PubMed ID: 23391148
[TBL] [Abstract][Full Text] [Related]
4. Tissue pO2 of orthotopic 9L and C6 gliomas and tumor-specific response to radiotherapy and hyperoxygenation.
Khan N; Li H; Hou H; Lariviere JP; Gladstone DJ; Demidenko E; Swartz HM
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):878-85. PubMed ID: 19136221
[TBL] [Abstract][Full Text] [Related]
5. Repeated assessment of orthotopic glioma pO(2) by multi-site EPR oximetry: a technique with the potential to guide therapeutic optimization by repeated measurements of oxygen.
Khan N; Mupparaju S; Hou H; Williams BB; Swartz H
J Neurosci Methods; 2012 Feb; 204(1):111-117. PubMed ID: 22079559
[TBL] [Abstract][Full Text] [Related]
6. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
Wu J; Waxman DJ
Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
[TBL] [Abstract][Full Text] [Related]
7. Skeletal muscle and glioma oxygenation by carbogen inhalation in rats: a longitudinal study by EPR oximetry using single-probe implantable oxygen sensors.
Hou H; Khan N; Lariviere J; Hodge S; Chen EY; Jarvis LA; Eastman A; Williams BB; Kuppusamy P; Swartz HM
Adv Exp Med Biol; 2014; 812():97-103. PubMed ID: 24729220
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
Doloff JC; Chen CS; Waxman DJ
Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
[TBL] [Abstract][Full Text] [Related]
9. Effect of hyperoxygenation on tissue pO2 and its effect on radiotherapeutic efficacy of orthotopic F98 gliomas.
Khan N; Mupparaju S; Hekmatyar SK; Hou H; Lariviere JP; Demidenko E; Gladstone DJ; Kauppinen RA; Swartz HM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1193-200. PubMed ID: 20813466
[TBL] [Abstract][Full Text] [Related]
10. Monitoring oxygen levels in orthotopic human glioma xenograft following carbogen inhalation and chemotherapy by implantable resonator-based oximetry.
Hou H; Krishnamurthy Nemani V; Du G; Montano R; Song R; Gimi B; Swartz HM; Eastman A; Khan N
Int J Cancer; 2015 Apr; 136(7):1688-96. PubMed ID: 25111969
[TBL] [Abstract][Full Text] [Related]
11. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
Wu J; Jordan M; Waxman DJ
BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
[TBL] [Abstract][Full Text] [Related]
12. Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.
Doloff JC; Khan N; Ma J; Demidenko E; Swartz HM; Jounaidi Y
Curr Cancer Drug Targets; 2009 Sep; 9(6):777-88. PubMed ID: 19754361
[TBL] [Abstract][Full Text] [Related]
13. Recurrent low-dose chemotherapy to inhibit and oxygenate head and neck tumors.
Khan N; Hou H; Hodge S; Kuppusamy M; Chen EY; Eastman A; Kuppusamy P; Swartz HM
Adv Exp Med Biol; 2014; 812():105-111. PubMed ID: 24729221
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy in conjunction with 7-hydroxystaurosporine: a multimodal approach with tumor pO2 as a potential marker of therapeutic response.
Khan N; Mupparaju SP; Hou H; Lariviere JP; Demidenko E; Swartz HM; Eastman A
Radiat Res; 2009 Nov; 172(5):592-7. PubMed ID: 19883227
[TBL] [Abstract][Full Text] [Related]
15. EPR Oximetry for Investigation of Hyperbaric O2 Pre-treatment for Tumor Radiosensitization.
Williams BB; Hou H; Coombs R; Swartz HM
Adv Exp Med Biol; 2016; 923():367-374. PubMed ID: 27526165
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.
Doloff JC; Waxman DJ
BMC Cancer; 2015 May; 15():375. PubMed ID: 25952672
[TBL] [Abstract][Full Text] [Related]
17. Quantitative imaging of pO
Yasui H; Kawai T; Matsumoto S; Saito K; Devasahayam N; Mitchell JB; Camphausen K; Inanami O; Krishna MC
Free Radic Res; 2017 Oct; 51(9-10):861-871. PubMed ID: 29076398
[TBL] [Abstract][Full Text] [Related]
18. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
Jordan M; Waxman DJ
Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
[TBL] [Abstract][Full Text] [Related]
19. Repeated tumor pO(2) measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapy.
Hou H; Lariviere JP; Demidenko E; Gladstone D; Swartz H; Khan N
Radiother Oncol; 2009 Apr; 91(1):126-31. PubMed ID: 19013657
[TBL] [Abstract][Full Text] [Related]
20. Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models.
Tran LB; Cao-Pham TT; Jordan BF; Deschoemaeker S; Heyerick A; Gallez B
J Cell Mol Med; 2019 Mar; 23(3):1908-1916. PubMed ID: 30575283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
